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Emil Kraepelin’s demarcation between dementia praecox 
and manic depressive illness deﬁ ned aﬀ ective disorder 
as a remitting and recurring disease. He considered that 
only long-term outcome was useful in assessing accuracy 
of diagnosis and treatment response in patients.1 The 
more recent interest in the outcome of single mood 
episodes probably indicates motives to register and 
market drugs rather than assisting clinical practice. This 
interest has resulted in many 4–8 week randomised 
trials but few well designed long-term studies in patients 
with depression.
There is now increasing evidence that Kraepelin was 
right. Mood disorders are generally recurring, and 
the relevant measure of clinical success is long-term 
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after catheter removal; infections and febrile episodes 
potentially related to treatment; catheter blockage; 
extended hospital stay; and residual incontinence 
at 3 months. 7 day bladder drainage after repair of 
simple ﬁ stulas was therefore found to be non-inferior 
to 14 day drainage, indicating that 7 day drainage 
is a safe and eﬀ ective way to manage postoperative 
bladder drainage without any substantial increase in 
complications. The crucial stage in wound healing, that 
is mobilisation of ﬁ broblasts, granulation formation, 
and neovascularisation, occurs at 5 days, with 
inﬂ ammation generally resolving after 7 days.2,6 
The ﬁ ndings of Barone and colleagues’ study1 will be 
welcome news to ﬁ stula surgeons who have agonised 
over the absence of capacity to care for patients, and 
the fact that patients with ﬁ stulas are often relegated 
to the bottom of theatre lists4 that are frequently 
loaded with emergencies. Reduction of postoperative 
catheterisation from 14 days to 10 days without a 
substantial increase in failure has been estimated 
to increase the number of patients with ﬁ stulas 
undergoing surgical repair by almost 30%3 without 
any increase in capital investment.3,4 Because duration 
of bladder catheterisation is a key determinant of the 
length of hospital stay, which aﬀ ects treatment costs 
and use of hospital beds,6–9 a halving of the duration of 
bladder drainage would increase the turnover of women 
getting the opportunity for care. However, possible 
confounding factors such as inadequacy of consumable 
supplies, anaesthesia, and nursing services would need 
to be addressed3,4,8 for the full beneﬁ ts of such a change 
in practice to be realised. The socioeconomic beneﬁ t 
of reduced hospital stay, from the perspectives of both 
patients and health systems, can be enormous in the 
setting of poorly resourced countries.4
A shortened duration of bladder drainage after simple 
ﬁ stula repair without an increase in the number of 
breakdowns is most welcome news to patients with 
ﬁ stulas and their caregivers. If the results of Barone 
and colleagues’ study can be reproduced in another 
multicentre randomised controlled trial, adoption of 
its conclusions into clinical practice would substantially 
expand our capacity to care for patients with ﬁ stulas. 
My hope is that, in the near future, obstetric ﬁ stula 
surgeons will have the evidence-based conﬁ dence 
to reduce the duration of postoperative bladder 
drainage without any anxiety about increased repair 
breakdowns.
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functioning rather than the outcome of a single mood 
episode.2 In secondary and tertiary care, less than a third 
of patients recover and remain well in the 18 months 
after an episode of depression,3 whereas in general 
practice and community studies, the proportion of 
patients with recurrence is between 35% and 65%.4 
Treatment needs to focus on maintenance and 
prevention of relapse as well as on the acute mood 
episode.
The most established treatment for prevention of 
relapse and recurrence is maintenance antidepressant 
medication. Studies have consistently reported a 
reduction in the odds of relapse of about 50–70%.5,6 
However, many patients might not wish to remain 
on medication or cannot tolerate the side-eﬀ ects. 
Alternative non-medication strategies would obviously 
be desirable.
Mindfulness-based cognitive therapy (MBCT) was 
developed as an explicit intervention to reduce relapse 
and recurrence in depression. MBCT teaches people who 
have had depression that negative feelings and thoughts 
will recur and that, rather than worrying or ruminating 
about these experiences, it is possible to become aware 
of and disengage from them, thereby preventing a 
downward spiral into depression.7 Although cognitive 
beh avioural therapy and interpersonal therapy also 
have evidence of eﬃ  cacy in the prevention of relapse in 
depressed patients8 neither were developed speciﬁ cally 
for this purpose.
Willem Kuyken and colleagues’ study,9 published in 
The Lancet, of mindfulness-based cognitive therapy in 
the prevention of depressive relapse or recurrence is 
therefore timely. It is a pragmatic long-term study done 
in general practice, where most depression is treated. 
The randomised trial compared MBCT with maintenance 
antidepressants in a large sample of patients with 
recurrent depression in the UK. 212 patients were 
randomly assigned to MBCT and 212 to maintenance 
antidepressant treatment, and the time to relapse 
or recurrence of depression did not diﬀ er between 
treatment groups over 24 months (hazard ratio 0·89, 
95% CI 0·67–1·18). The authors’ interpretation of the 
ﬁ ndings is carefully worded: there is no support for 
MBCT being superior to maintenance antidepressants 
in preventing depressive relapse. Despite this apparent 
negative result, the ﬁ ndings have substantial clinical 
signiﬁ cance.
Kuyken and colleagues’ ﬁ ndings, if benchmarked 
against the studies of maintenance antidepressant 
therapy, provide evidence that MBCT might oﬀ er a 
similar ongoing protective eﬀ ect as that of maintenance 
antidepressants. MBCT therefore provides an alternative 
eﬀ ective treatment for patients who cannot tolerate 
or do not wish to have maintenance antidepressant 
therapy. Because it is a group treatment that reduces 
costs and the number of trained staﬀ  needed, it might 
be feasible to oﬀ er MBCT as a choice to patients in 
general practice. Pooling all trial data comparing MBCT 
and maintenance antidepressant treatment (which is 
limited to three studies), as Kuyken and colleagues did,9 
resulted in a risk reduction of 24% for MBCT compared 
with maintenance antidepressants (risk ratio 0·76 
95% CI 0·59–0·98). Perhaps all patients with recurrent 
depression should be oﬀ ered MBCT.
We therefore have a promising new treatment that 
is reasonably cost eﬀ ective and applicable to the large 
group of patients with recurrent depression. The next 
obvious question is whether there are speciﬁ c eﬀ ects 
of MBCT that confer this decreased risk of relapse or 
whether any structured group psychotherapy would 
produce similar results. Ongoing studies of mechanism 
of action are promised by the authors. If the research 
in long-term treatment of personality disorders is any 
guide, they are likely to ﬁ nd that general factors such as 
a manualised approach, active supportive therapists, a 
focus on patients’ sense of agency and management of 
life situations are most important,10 rather than speciﬁ c 
factors related to mindfulness theory.
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What do I know? That question was the impulse behind 
Michel de Montaigne’s essays. Whether he was writing 
about illness, vanity, drunkenness, or sleep, Montaigne 
wrote with informality, intimacy, and incisive 
knowledge. As another great essayist William Hazlitt 
said of Montaigne, “he did not set up for a philosopher, 
wit, or orator or moralist but he became all these by 
merely daring to tell us whatever passed through his 
mind”. In the centuries since Montaigne mastered 
this form, the essay, a discursive and intimate form of 
personal reﬂ ection, has remained a powerful way to 
inform, engage, and entertain readers.
So what do you know? And why does it matter 
to clinical medicine or global health now? We 
want you to tell us by entering The Lancet’s annual 
essay competition, the Wakley Prize—named after 
Thomas Wakley, the radical founding Editor of 
The Lancet. The Prize will be awarded to the best essay 
on any clinical topic of importance to health. Whether 
your focus is global or local, we expect provocative 
originality, ﬁ ne writing, and invigorating argument. 
We’re looking for fresh writing that engages both our 
hearts and minds about what matters most to you in 
contemporary medicine.
We invite submissions from anyone around the world 
working in a health-related ﬁ eld, whether you’re a 
student, established in mid-career, or approaching the end 
of a lifetime of service in health care or biomedical science. 
Allow your imagination the freedom to develop your 
idea into the informal prose of an excellent essay. Essays 
of no more than 2000 words should be submitted via 
The Lancet’s electronic submission system by Oct 26, 2015, 
with “Wakley Prize” selected as the publication type. 
Essays should not contain any information that might 
identify individual patients. Entries will be anonymised, 
and judged by the editors of The Lancet. The winner of 
the Wakley Prize will receive £2000, and the essay will be 
published in The Lancet and feature in our podcast. We will 
only accept one submission per author. We look forward 
to reading your essays and ﬁ nding out what you know 
and why it matters.
Joanna Palmer, Philippa Berman, Priya Venkatesan
The Lancet, London EC2Y 5AS, UK 
The Wakley Prize, 2015: what do you know?
To submit an essay go to 
http://ees.elsevier.com/
thelancet/default.asp
Please ensure that all 
information identifying the 
author is removed from the 
essay document
Depression remains a disabling condition with high 
prevalence and a large clinical burden. Despite the 
increased use of drugs, the long-term outcome of mood 
disorders has not improved in the modern era.11 Having 
an alternative non-medication strategy to reduce relapse 
is an important means to help patients with depression.
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